Castro VM

Language: Spanish
References: 16
Page: 389-394
PDF size: 501.49 Kb.

ABSTRACT

The cystic fibrosis is an autosomic recessive disease, caused by a mutation localized in chromosome 7, distinguished by lesions in gastrointestinal tract and pulmonary affection. The criteria for diagnosis are evidence of chloride channel dysfunction (sweat chloride ›60 mEq/L). There is a direct relation with the function of the CFTR gene; the knowledge of CFTR brings information of pulmonary epithelium damage and the susceptibility of the host to be colonized by germens with a difficult treatment (ie Pseudomona aeurginosa). Antimicrobian therapy avoid the chronic infection and also delay the deterioration of the patient.

REFERENCES

1. Antiñolo G, Chillón M, Sánchez J. Genética de la fibrosis quística. En: Dapena Fernández FJ (ed.). Fibrosis quística. Atención integral, manejo clínico y puesta al día. Granada: Editorial Alhulia Salobreña; 1998. p. 41-82.

2. De Gracia J, Álvarez A, Mata F, Guarner L, Vendrell M, Gartner S, et al. Fibrosis quística del adulto: estudio de 111 pacientes. Med Clin (Barc). 2002;119:605-9.[Medline][Artículo]

3. Denton M, Wilcox MH. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother. 1997;40:468-74.[Medline].

4. Donaldson SH, Boucher RC. Update on the pathogenesis of cystic fibrosis lung disease. Curr Opin Pulm Med. 2003;9:486-91.[Medline]

5. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749-67.[Medline].

6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91-100.[Medline].

7. Gibson LE, Cooke RE. A test for concentration of electrolytes in cystic fibrosis utilizing pilocarpine by iontophoresis. Pediatrics 1959; 23: 545-563.

8. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pul-monary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;15:918-51.

9. Matsui H, Verghese MW, Kesimer M, et al:Reduced threedimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J Immunol 2005; 175: 1090–1099.

10. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288:1251-4.[Medline]

11. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect. 2002;17:47-56.[Medline].

12. Ratjen F, Doring G. Cystic fibrosis. Lancet. 2003;22:681-9.

13. Saiman L, Siegel J. Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control. 2003;31 3 Suppl:S1-62.

14. Tsui LC, Buchwald M, Barker D, Braman JC, Knowlton R, Schumm JW, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science. 1985;29:1054-7.

15. Vázquez C. La prueba del sudor en el diagnóstico de la fibrosis quística. En: Dapena Fernández FJ (ed.). Fibrosis quística. Atención integral, manejo clínico y puesta al día. Granada: Editorial Alhulia Salobreña; 1998. p. 311-324.

16. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest. 2004;125 1 Suppl:S1-39.